Literature DB >> 20438609

Prerequisites for implementing cardiovascular absolute risk assessment in general practice: a qualitative study of Australian general practitioners' and patients' views.

Qing Wan1, Mark F Harris, Nicholas Zwar, Sanjyot Vagholkar, Terry Campbell.   

Abstract

BACKGROUND: Although recommended in clinical practice guidelines, cardiovascular absolute risk (CVAR) assessment is still used infrequently in Australian general practice. One reason is the lack of an implementation strategy. Given the lack of published reports on the implementation of CVAR worldwide, the aim of this study was to explore the views of general practitioners (GPs) and patients on prerequisites for successfully implementing CVAR assessment in general practice.
METHODS: Multiple data involving GPs and patients were collected using focus groups (FGs) in three divisions of General Practice in Sydney between 2005 and 2006. Both GPs' and patients' opinions were analysed using thematic analysis.
RESULTS: Twenty-two GPs participated in three GP FGs and 26 patients in three patient FGs. Many GPs thought that an initial cardiovascular risk screening could start from 40 years old while some patients thought it should start even younger. Targeting patients with known risk factors was supported by most GPs although some also stressed the importance of reaching those of unknown risk. For new patients or patients presenting for other problems, another visit for CVAR risk assessment and discussion was preferred by most GPs. A strong GP-patient relationship, common ground on priorities between GPs and their patients, patient awareness of cardiovascular risk and motivation were seen as important by both GPs and patients to the implementation of CVAR assessment.
CONCLUSIONS: Addressing the appropriate selection of patients and time for implementing CVAR assessment requires a consideration of multiple factors. GPs see it as a process that may need to be staged over more than one consultation and requiring appropriate strategies.

Entities:  

Mesh:

Year:  2010        PMID: 20438609     DOI: 10.1111/j.1365-2753.2009.01170.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  5 in total

1.  GPs' opinions of health assessment instruments for people with intellectual disabilities: a qualitative study.

Authors:  Esther J Bakker-van Gijssel; Tim C Olde Hartman; Peter Lbj Lucassen; Francine van den Driessen Mareeuw; Marianne K Dees; Willem Jj Assendelft; Henny Mj van Schrojenstein Lantman-de Valk
Journal:  Br J Gen Pract       Date:  2016-12-19       Impact factor: 5.386

2.  The Treatment of cardiovascular Risk in Primary care using Electronic Decision supOrt (TORPEDO) study-intervention development and protocol for a cluster randomised, controlled trial of an electronic decision support and quality improvement intervention in Australian primary healthcare.

Authors:  David Peiris; Tim Usherwood; Katie Panaretto; Mark Harris; Jenny Hunt; Bindu Patel; Nicholas Zwar; Julie Redfern; Stephen Macmahon; Stephen Colagiuri; Noel Hayman; Anushka Patel
Journal:  BMJ Open       Date:  2012-11-19       Impact factor: 2.692

3.  Evaluation of clinical quality improvement interventions: feasibility of an integrated approach.

Authors:  Sandeep Reddy; Kevin Mc Namara; Mary Malakellis; Tim Denton; Cathy McDonald; Jane Opie; Andrew Sanigorski; Vincent Versace
Journal:  Pilot Feasibility Stud       Date:  2019-01-10

4.  The response to receiving phenotypic and genetic coronary heart disease risk scores and lifestyle advice - a qualitative study.

Authors:  Guy Shefer; Barbora Silarova; Juliet Usher-Smith; Simon Griffin
Journal:  BMC Public Health       Date:  2016-12-03       Impact factor: 3.295

5.  General practitioners' perspectives on the prevention of cardiovascular disease: systematic review and thematic synthesis of qualitative studies.

Authors:  Irene Ju; Emily Banks; Bianca Calabria; Angela Ju; Jason Agostino; Rosemary J Korda; Tim Usherwood; Karine Manera; Camilla S Hanson; Jonathan C Craig; Allison Tong
Journal:  BMJ Open       Date:  2018-11-01       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.